Cargando…
Effects of secukinumab on bone mineral density and bone turnover biomarkers in patients with ankylosing spondylitis: 2-year data from a phase 3 study, MEASURE 1
BACKGROUND: Axial spondyloarthritis including ankylosing spondylitis (AS) is characterized by chronic inflammation and new bone formation in the axial skeleton. On the other hand, bone loss, osteoporosis and an increased risk of vertebral fractures is known to frequently occur in AS. In the MEASURE...
Autores principales: | Braun, Jürgen, Buehring, Bjoern, Baraliakos, Xenofon, Gensler, Lianne S., Porter, Brian, Quebe-Fehling, Erhard, Haemmerle, Sibylle |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8670267/ https://www.ncbi.nlm.nih.gov/pubmed/34903218 http://dx.doi.org/10.1186/s12891-021-04930-1 |
Ejemplares similares
-
Achievement of Remission Endpoints with Secukinumab Over 3 Years in Active Ankylosing Spondylitis: Pooled Analysis of Two Phase 3 Studies
por: Baraliakos, Xenofon, et al.
Publicado: (2020) -
Impact of baseline C-reactive protein levels on the response to secukinumab in ankylosing spondylitis: 3-year pooled data from two phase III studies
por: Braun, Jürgen, et al.
Publicado: (2018) -
The relationship between inflammation and new bone formation in patients with ankylosing spondylitis
por: Baraliakos, Xenofon, et al.
Publicado: (2008) -
Secukinumab shows sustained efficacy and low structural progression in ankylosing spondylitis: 4-year results from the MEASURE 1 study
por: Braun, Jürgen, et al.
Publicado: (2019) -
Effects of infliximab on markers of inflammation and bone turnover and associations with bone mineral density in patients with ankylosing spondylitis
por: Visvanathan, S, et al.
Publicado: (2008)